|
tipas |
leidinys |
55 |
Žurnalas |
Smith A, Bird G. The compatibility of diazepam with infusion fluids and their containers. J Clin Hosp Pharm 1982 ; 7: 181-186. |
58 |
Žurnalas |
Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161. |
59 |
Žurnalas |
Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
73 |
Žurnalas |
Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159. |
93 |
Žurnalas |
Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188. |
190 |
Žurnalas |
Lee MG. Sorption of four drugs to polyvinyl chloride and polybutadiene intravenous administration sets. Am J Hosp Pharm 1986 ; 43: 1945-1950. |
198 |
Žurnalas |
Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520. |
226 |
Žurnalas |
Walker SE, DeAngelis C, Iazzetta J. Stability and compatibility of combinations of hydromorphone and a second drug. Can J Hosp Pharm 1991 ; 44: 289-295. |
266 |
Žurnalas |
Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
299 |
Žurnalas |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
300 |
Žurnalas |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
348 |
Žurnalas |
Hancock BG, Black CD. Effect of a polyethylene-lined administration set on the avaibility of diazepam injection. Am J Hosp Pharm 1985 ; 42: 335-339. |
350 |
Žurnalas |
Martens HJ, De Goede PN, Van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm 1990 ; 47: 369-373. |
351 |
Žurnalas |
Yliruusi JK, Uotila JA, Kristoffersson ER. Effect of flow rate and type of IV container on adsorption of diazepam to IV administration systems. Am J Hosp Pharm 1986 ; 43: 2795-2799. |
352 |
Žurnalas |
Yliruusi JK, Uotilo JA, Kristoffersson ER. Effect of tubing length on adsorption of diazepam to polyvinyl chloride administration sets. Am J Hosp Pharm 1986 ; 43: 2789-2794. |
402 |
Žurnalas |
Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821. |
476 |
Žurnalas |
Knapp AJ, Mauro VF, Alexander KS. Incompatibility of ketorolac tromethamine with selected postoperative drugs. Am J Hosp Pharm 1992 ; 49: 2960-2962. |
496 |
Žurnalas |
Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746. |
616 |
Žurnalas |
Jump WG, Plaza VM, Poremba A. Compatibility of nalbuphine hydrochloride with other preoperative medications. Am J Hosp Pharm 1982 ; 39: 841-843. |
621 |
Žurnalas |
Yliruusi JK, Sothmann AG, Laine RH, Rajasilta RA, Kristoffersson ER. Sorptive loss of diazepam and nitroglycerin from solutions to three types of containers. Am J Hosp Pharm 1982 ; 39: 1018-1021. |
660 |
Žurnalas |
Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232. |
711 |
Žurnalas |
Cloyd JC, Vezeau C, Miller KW. Avaibility of diazepam from plastic containers. Am J Hosp Pharm 1980 ; 37: 492-496. |
712 |
Žurnalas |
Parker WA, MacCara ME. Compatibility of diazepam with intravenous fluid containers and administration sets. Am J Hosp Pharm 1980 ; 37: 496-500. |
730 |
Žurnalas |
Allen LV, Saul Levinson R, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943. |
731 |
Žurnalas |
Morris ME. Compatibility and stability of diazepam injection following dilution with intravenous fluids. Am J Hosp Pharm 1978 ; 35: 669-672. |
921 |
Žurnalas |
Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292. |
939 |
Žurnalas |
Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170. |
1041 |
Žurnalas |
Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951. |
1057 |
Žurnalas |
Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207. |
1067 |
Žurnalas |
Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110. |
1102 |
Žurnalas |
Cossum PA, Roberts MS. Availability of isosorbide dinitrate, diazepam and chlormethiazole, from i.v. delivery systems. Eur J Clin Pharmacol 1981 ; 19: 181-185. |
1173 |
Žurnalas |
Kowaluk EA, Roberts MS, Blackburn HD, Polack AE. Interactions between drugs and polyvinyl chloride infusion bags. Am J Hosp Pharm 1981 ; 38: 1308-1314. |
1182 |
Žurnalas |
Mason NA, Cline S, Hyneck ML, Berardi RR, Ho NFH, Flynn GL. Factors affecting diazepam infusion: solubility, administration-set composition, and flow rate. Am J Hosp Pharm 1981 ; 38: 1449-1454. |
1199 |
Žurnalas |
Smith FM, Nuessle NO. Stability of diazepam injection repackaged in glass unit-dose syringes. Am J Hosp Pharm 1982 ; 1687-1690. |
1200 |
Žurnalas |
Chaudry IA, Bruey KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742. |
1232 |
Žurnalas |
Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236. |
1269 |
Žurnalas |
DeMuynck C, De Vroe C, Remon JP, Colardyn F. Binding of drugs to end-line filters: a study of four commonly administered drugs in intensive care units. J Clin Pharm Ther 1988 ; 13: 335-340. |
1271 |
Žurnalas |
Mathot F, Bonnard J, Paris P, Bosly J. Reliable continuous IV perfusion system for diazepam. J Pharm Belg 1982 ; 37: 153-156. |
1366 |
Žurnalas |
Jeglum EL, Winter E, Kotos M. Nafcillin sodium incompatibility with acidic solutions. Am J Hosp Pharm 1981 ; 38: 462,464. |
1424 |
Žurnalas |
Gottwald MD, Akerd LC, Liu PK, Orsulak PJ, Corry M, Bacchetti P, Fields SM, Loxenstein DH, Alldredge BK. Prehospital stability of diazepam and lorazepam. Am J Emerg Med 1999 ; 17: 333-337. |
1438 |
Žurnalas |
Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841. |
1472 |
Žurnalas |
Salomies HEM, Heinonen RM, Toppila MAI. Sorptive loss of diazepam, nitroglycerin and warfarin sodium to polypropylene-lined infusion bags (Softbags). Int J Pharm 1994 ; 110: 197-201. |
1512 |
Laboratorija |
Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015 |
1522 |
Laboratorija |
Macoflex N® Maco Pharma 2001 |
1603 |
Žurnalas |
Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223. |
1625 |
Žurnalas |
Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321. |
1662 |
Žurnalas |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37. |
1712 |
Žurnalas |
Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233. |
1713 |
Žurnalas |
Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315. |
1721 |
Žurnalas |
Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72. |
1803 |
Žurnalas |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85. |
1925 |
Žurnalas |
Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519. |
1960 |
Žurnalas |
Kambia NK, Dine T, Dupin-Spriet T, Gressier B, Luycks M, Goudaliez F, Brunet C. Compatibility of nitroglycerin, diazepam and chlorpromazine with a new multilayer material for infusion containers. J Pharm Biomed Anal 2005 ; 37: 259-264. |
1974 |
Žurnalas |
Chandler SW, Trissel LA, Weinstein SM Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171. |
2087 |
Žurnalas |
Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20. |
2090 |
Žurnalas |
Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196. |
2262 |
Žurnalas |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
2269 |
Žurnalas |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
2324 |
Žurnalas |
Treleano A, Wolz G, Brandsch R, Welle F. Investigation into the sorption of nitroglycerin and diazepam into PVC tubes and alternative tube materials during application Int J Pharm 2009 ; 369, 1-2 : 30-37 |
3012 |
Žurnalas |
Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220. |
3184 |
Laboratorija |
Hyaluronidase (Hyalase®) - Summary of Product characteristics. CP Pharmaceuticals 2005 |
3216 |
Žurnalas |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18 |
3249 |
Žurnalas |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
3332 |
Laboratorija |
Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012 |
3408 |
Žurnalas |
Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21. |
3474 |
Laboratorija |
Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009 |
3501 |
Laboratorija |
Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics Pfizer 2011 |
3521 |
Laboratorija |
Tramadol® - Summary of Product Characteristics. Beacon Pharmaceuticals 2012 |
3539 |
Laboratorija |
Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013 |
3540 |
Laboratorija |
Heparin sodium - Summary of Product Characteristics. Wockhardt 2010 |
3560 |
Laboratorija |
Linezolid (Zyvox®) - Summary of Product Characteristics Pharmacia 2013 |
3564 |
Laboratorija |
Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012 |
3571 |
Žurnalas |
Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47. |
3599 |
Laboratorija |
Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercry 2013 |
3607 |
Laboratorija |
Esmolol hydrochloride for injection - Summary of Product Characteristics AOP Orphan Pharmaceuticals AG 2013 |
3614 |
Laboratorija |
Nicardipine Injection - Summary of Product Characteristics American Regent Inc 2013 |
3617 |
Laboratorija |
Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011 |
3672 |
Laboratorija |
Nalbuphine Mylan - Résumé des caractéristiques du produit Mylan SAS 2016 |
3766 |
Žurnalas |
Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165. |
3767 |
Žurnalas |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172. |
3824 |
Žurnalas |
Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98 |
3885 |
Žurnalas |
Su-Eon Jin, Siwon You, Seungho Jeon, Sung-Joo Hwang. Diazepam sorption to PVC- and non-PVC-based tubes in administration sets with quantitative determination using a high-performance liquid chromatographic method. Int J Pharm 2016 ; 506 : 414-419. |
3932 |
Laboratorija |
Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015 |
3941 |
Laboratorija |
Nicardipine - Summary of Product Characteristics Concordia International 2017 |
3964 |
Žurnalas |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33. |
4154 |
Laboratorija |
Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018 |
4319 |
Žurnalas |
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337. |
4428 |
Žurnalas |
Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132. |
4435 |
Žurnalas |
Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27. |
4603 |
Žurnalas |
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234. |
4650 |
Laboratorija |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021 |
4700 |
Laboratorija |
Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics AS Kalceks 2022 |
4742 |
Žurnalas |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255. |